CEL-SCI Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVM NYSE American 2836 cel-sci.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CEL-SCI Corporation

CEL-SCI Reports Fiscal First Quarter 2026 Results - Feb 18th, 2026 7:00 am
Cel-Sci: Fiscal Q1 Earnings Snapshot - Feb 17th, 2026 3:14 pm
CEL-SCI Reports Fiscal 2025 Results - Dec 29th, 2025 7:00 am
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 - Oct 20th, 2025 7:00 am
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference - Oct 10th, 2025 6:00 am
CEL-SCI Announces Closing of $10 Million Public Offering - Aug 29th, 2025 10:52 am
CEL-SCI Announces Pricing of $10 Million Public Offering - Aug 27th, 2025 8:35 pm
CEL-SCI Announces Proposed Public Offering - Aug 27th, 2025 3:25 pm
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results - Aug 14th, 2025 8:45 am
Cel-Sci: Fiscal Q3 Earnings Snapshot - Aug 14th, 2025 7:37 am
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline - Aug 13th, 2025 7:15 am
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules - Jul 14th, 2025 2:05 pm
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules - Jul 11th, 2025 10:16 am
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer - Jul 11th, 2025 7:15 am
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Jun 18th, 2025 7:00 am
CEL-SCI Announces Closing of Public Offering - May 23rd, 2025 2:05 pm
CEL-SCI Announces Pricing of Public Offering - May 21st, 2025 6:14 pm
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - May 21st, 2025 6:00 am
CEL-SCI Announces Combination of Common Stock - May 19th, 2025 12:40 pm
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - May 15th, 2025 7:00 am